Prevalence and Predictive Factors of Anemia after Renal Transplantation: A Moroccan Report

Radoui, A.; Skalli, Z.; Haddiya, I.; Benamar, L.; Ezzaitouni, F.; Ouzeddoun, N.; Bayahia, R.; Rhou, H.

doi:10.1016/j.transproceed.2010.07.092

Cited by 10 publications

(3 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In both cohorts, statistically significant differences in serum creatinine levels and GFR were found between values at −12 months and upon reinitiating dialysis. In agreement with other studies [ 17 , 30 – 32 ], the prevalence of anaemia was high but there was a decrease over the 8-year study period, with a mean haemoglobin value of 11.6 g/dL [7.2 mmol/L] in 2001 versus 12.3 g/dL [7.6 mmol/L] in 2009 at −12 months and 9.6 g/dL [6.0 mmol/L] in 2001 versus 10.6 g/dL [6.6 mmol/L] in 2009 at the time of restarting dialysis. A recent study carried out in Spain has shown that failed transplant patients start dialysis with more severe anaemia than patients entering dialysis for the first time.…”

Section: Discussionsupporting

confidence: 94%

Clinical profile and post-transplant anaemia in renal transplant recipients restarting dialysis after a failed graft: changing trends between 2001 and 2009

Arias

Hernández

Guirado

et al. 2013

Clinical Kidney Journal

View full text Add to dashboard Cite

BackgroundThe aim of this study was to compare the clinical profile, outcome and the prevalence and management of anaemia between two cohorts of renal transplant patients with graft failure restarting dialysis in 2001 and 2009.MethodsCross-sectional, observational, retrospective and multicentre study of 397 patients in the 2001 cohort and 222 in the 2009 cohort. Data were recorded at 0, 3, 6, 9 and 12 months before the onset of dialysis resumption and during the first 90 days after restarting dialysis (mortality and hospital admission).ResultsPatients in the 2009 cohort were older at the time of inclusion in the study and transplantation, and restarted dialysis therapy with a significantly better glomerular filtration rate. In both cohorts, there was a rapid deterioration of renal function with statistically significant differences in serum creatinine and glomerular filtration rate between the monthly intervals −12 and 0. The mean haemoglobin value at −12 months was 11.6 g/dL [7.2 mmol/L] in the 2001 cohort when compared with 12.3 g/dL [7.6 mmol/L] in the 2009 cohort, and at the time of restarting dialysis 9.6 g/dL [6.0 mmol/L] versus 10.6 g/dL [6.6 mmol/L]. The percentage of patients treated with erythropoiesis-stimulating agents, at any time during the 12 months before readmission to dialysis, increased significantly from 61.5% in the 2001 cohort to 96% in the 2009 cohort. There were no significant differences between the 2001 and 2009 cohorts in mortality rate (8.8 versus 9.0%) or hospital admission (31.5 versus 31.1%) during the study time.ConclusionsAt restarting dialysis, the proportion of patients with anaemia (and its severity) due to progressive graft nephropathy decreased over the past 8 years, increasing significantly the percentage of patients treated with erythropoietin. Differences in morbimortality after dialysis resumption were not observed, this is probably due to an increase in the age of donors and recipients.

show abstract

Section: Discussionsupporting

confidence: 94%

Clinical profile and post-transplant anaemia in renal transplant recipients restarting dialysis after a failed graft: changing trends between 2001 and 2009

Arias

Hernández

Guirado

et al. 2013

Clinical Kidney Journal

View full text Add to dashboard Cite

show abstract

“…24 Late PTA is usually associated with decreased graft function and occurrence of renal insufficiency. 25 In the present study, there was a significant improvement in the hemoglobin level at post-transplant one, six and 12 months as compared to the pre-transplant and it was significant (p<0.001), which was consistent with Radoui et al 26 who reported the pre-transplant Hb improvement from 10.2 g/dl at one month to 12.8 g/dl at sixth month and then to 13.2 g/dl at one year.…”

Section: Discussionsupporting

confidence: 91%

Post kidney transplant hematologic abnormalities and association of post-transplant anemia with graft function

Laxminarayana,

Jayaram,

Swaminathan

et al. 2024

F1000Res

View full text Add to dashboard Cite

Background Haematological abnormalities following renal transplantation are frequently observed and have a significant effect on survival and graft outcomes. The pattern of haematological abnormalities varies globally. Few studies have been conducted in Asian countries. We aimed to evaluate the patterns of haematological abnormalities in post-transplant recipients in our center during the first year after post-renal transplant and the association of post-transplant anemia with graft function. Methods This single-center retrospective study was conducted on renal transplantation recipients between 2014 and 2019. The study included all patients who received kidney transplants from live/cadaveric donors and had follow-up data collected up to 12 months after the transplant. The outcome studied was the prevalence of haematological abnormalities and the association between post-transplant anemia (PTA) and graft function in post-transplant recipients. Results A total of 106 renal transplant recipients were included in the study. The prevalence of PTA was 98% in the first week, 75% at one month, 35% at three months, 32% at six months, and 27% at 12 months. The other cytopenia cases were leukopenia (43.4%), thrombocytopenia (33.2%), and pancytopenia (15.1%). Post-transplant erythrocytosis was observed in 17.9% of patients. 18 patients with severe PTA in the first week of transplant had significant allograft dysfunction (p=0.04). Patients with and without PTA had similar graft functions at six and 12 months (p=0.50). Conclusions Haematological abnormalities are common in renal transplant recipients. PTA is highly prevalent during the first week and improves over time. Other haematological abnormalities observed were leukopenia, thrombocytopenia, pancytopenia, and post-transplant erythrocytosis. Leucopenia was primarily drug-induced, and thrombocytopenia and pancytopenia were frequently caused by infections in our cohort. Additionally, severe PTA was significantly associated with graft dysfunction in the first week post-transplant, whereas similar graft function was observed at 6 and 12 months post-transplant, irrespective of the presence or absence of PTA.

show abstract

“…Among special clinical populations, two studies examined HCV prevalence among those who had a renal transplant reporting estimates of 19% [ 56 ] and 10% [ 57 ]. HCV prevalence among HCC patients was 57% [ 55 ].…”

Section: Resultsmentioning

confidence: 99%

The Epidemiology of Hepatitis C Virus in the Maghreb Region: Systematic Review and Meta-Analyses

et al. 2015

View full text Add to dashboard Cite

ObjectiveTo systematically review and synthesize available epidemiological data on hepatitis C virus (HCV) prevalence and incidence in the Maghreb region and to estimate the country-specific population-level HCV prevalence.MethodsWe conducted a systematic review of HCV antibody prevalence and incidence in the Maghreb countries as outlined by the PRISMA guidelines. Meta-analyses were conducted using DerSimonian-Laird random-effect models with inverse variance weighting to pool HCV prevalence estimates among general population groups.ResultsWe identified 133 HCV prevalence measures and two HCV incidence measures. Among high risk groups, HCV prevalence ranged between 22% and 94% among people who inject drugs, 20% and 76% among dialysis patients, and 2% and 51% among hemophiliacs. Among intermediate-risk groups, considerable but widely variable HCV prevalence was found. Most common risk factors cited across studies were the duration of dialysis, number of transfusions, and having a history of surgery or dental work. The national HCV prevalence in Algeria was estimated at 0.3% (95%CI: 0.1–0.5), Libya 1.2% (95%CI: 1.1–1.3), Mauritania 1.1% (95%CI: 0–2.3), Morocco 0.8% (95%CI: 0.5–1.2), and Tunisia 0.6% (95%CI: 0.5–0.8).ConclusionsHCV prevalence in the Maghreb region of the Middle East and North Africa is comparable to that in developed countries of about 1%. HCV exposures appear often to be linked to medical care and are suggestive of ongoing transmission in such settings. Injecting drug use appears also to be a major, though not dominant, contributor to HCV transmission. Further research is needed to draw a more thorough understanding of HCV epidemiology, especially in the countries with limited number of studies. HCV prevention policy and programming in these countries should focus on the settings of exposure.

show abstract

Prevalence and Predictive Factors of Anemia after Renal Transplantation: A Moroccan Report

Cited by 10 publications

References 30 publications

Clinical profile and post-transplant anaemia in renal transplant recipients restarting dialysis after a failed graft: changing trends between 2001 and 2009

Clinical profile and post-transplant anaemia in renal transplant recipients restarting dialysis after a failed graft: changing trends between 2001 and 2009

Post kidney transplant hematologic abnormalities and association of post-transplant anemia with graft function

The Epidemiology of Hepatitis C Virus in the Maghreb Region: Systematic Review and Meta-Analyses

Contact Info

Product

Resources

About